Median time to progression for premenopausal patients was 3 months.

Patients and methods: We review records of 159 premenopausal patients receiving adjuvant chemotherapy from our practice.

There was no statistically significant difference in the mitotic activity between the postmenopausal and the premenopausal patients.

There was a statistically significant difference in the extent of necrosis in the tumours of postmenopausal and premenopausal patients.

Also, the precipitating event was most often sexual intercourse in premenopausal patients and increased intra-abdominal pressure in postmenopausal patients.

Conclusion: TAM resulted in additional benefit to premenopausal patients with node-positive ER-positive breast cancer who received the CMF polychemotherapy regimen.

The extent of necrosis also proved useful in prognostication among the premenopausal patients (p=0.0004).

Progesterone receptor levels were independent of menstrual status but the lowest PR positivity in premenopausal patients was observed during the late luteal phase.

Control endometrial tissues were obtained from premenopausal patients who had subserosal leiomyoma and NESC gene expression patterns may be altered in these women.

Hormonal therapy of malignant breast disease is an integral part of adjuvant as well as palliative treatment in postmenopausal as well as premenopausal patients.

Patients and methods: Three hundred fourteen premenopausal patients with ER-positive, node-positive breast cancer were enrolled between July 1979 and July 1989.

Although menopausal status alone was not a significant prognostic variable in regression analysis, 66% of premenopausal patients had a constellation of "poor" prognostic variables.

Premenopausal patients had a higher rate of lymph node metastases although this was not significant.